| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | MGC026 selected solid tumor indications | Phase 1 | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | MGC026 selected solid tumor indications | Phase 1 | — | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1 data readout example | MGC026 selected solid tumor indications | Phase 1 | — | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
MacroGenics, Inc.$4.81
+0.15 (+3.22%)
B 64Pipeline Score Undervalued Pharma · Commercial
Market Cap
287.94 M
EPS
-1.11
P/E Ratio
-
Value Trade
2.62 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
20.77 M
R&D Expenses
34.97 M
Operating CF
-35.81 M
Total Assets
217.87 M
Total Liabilities
196.68 M
Equity
21.20 M
D/E Ratio
12,345
9.69 %
Week
28.69 %
1 Month
163.37 %
3 Month
230.66 %
6 Month
-85.15 %
5 Year
-81.13 %
All Time
Cash Data
Cash Position
154.23 M
Monthly Burn
11.94 M
Runway
11.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
8.52 M
52 Week Range
1.19 - 4.64
% held by Insiders
3.54 %
% held by Institutions
69.9 %
Enterprise Value
238.93 M
Total Shares
63.59 M
Short %
7.8 %
Float Shares
61.43 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B64
Pipeline Score $2.5B
Pipeline ValueUndervalued
Valuation Signal21
Drugs Scored8.5x
rNPV / MCap Top 92%
Micro Cap (rank 73 of 905)
Percentile RankMacroGenics, Inc. holds a solid B-grade pipeline (64/100), with $23.7B risk-adjusted pipeline value, led by Lorigerlimab in Metastatic Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lorigerlimab Small molecule | Pancreatic Adenocarcinoma | Phase 2 | NCT07565155 | 19% | $7.7B | NOT YET_RECRUITING | 40 | - | - | Jun 1, 2031 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MGNX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MGNX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGNX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGNX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGNX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MGNX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MGNXMacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
MacroGenics announced it will receive a $24.5 million milestone payment from Sanofi following the FDA's accelerated approval of TZIELD for delaying insulin decline in children with type 1 diabetes. This approval enhances TZIELD's role as a disease-modifying therapy. The company is also eligible for up to $305 million in additional payments.
Read more →MGNXMacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
MacroGenics, Inc. has announced that its President and CEO, Eric Risser, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum. The event is scheduled for May 20, 2026, at 10:30 a.m. ET. Investors can access a webcast of the presentation on the company's website, which will also archive the presentation for 30 days post-event. This participation highlights MacroGenics' focus on developing innovative antibody-based therapeutics for cancer treatment.
Read more →MGNXMacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
MacroGenics reported its Q1 2026 financial results, highlighting a strategic divestiture of its manufacturing operations to enhance focus on drug discovery. The company anticipates up to $202.5 million from this and royalty monetization, supporting its pipeline and extending its cash runway through 2028. Despite a net loss, the ADC pipeline remains promising with several upcoming milestones.
Read more →MGNXMacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics has agreed to sell its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million. The deal includes the transfer of a manufacturing site and personnel, allowing MacroGenics to focus on its innovative pipeline. Bora plans to integrate the operations into its North American biologics strategy, ensuring continued service for existing clients.
Read more →MGNXMacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
MacroGenics has expanded its royalty purchase agreement with Sagard Healthcare Partners, receiving a $60 million upfront payment and potential future milestone payments based on ZYNYZ sales. ZYNYZ, a PD-1 inhibitor, is indicated for treating specific types of cancer. The agreement allows MacroGenics to retain other economic interests related to ZYNYZ.
Read more →MGNXcandidates in ongoing clinical trials the Company's ability to provide manufacturing services to its customers the uncertainties inherent in the initiation and enrollment of future clinical trials the availability of fin
MacroGenics, Inc. has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners, receiving an upfront payment of $60 million and the potential for an additional sales-based milestone of $20 million. This agreement pertains to future global net sales of its PD-1 inhibitor, ZYNYZ. The firm retains its economic interests in ZYNYZ, including development and regulatory milestones, while Sagard aims to recover its investment through sales. MacroGenics views this deal as a reinforcement of ZYNYZ's strategic importance.
Read more →MGNXmore information, please see the Company's website at www.macrogenics.com . MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking State
MacroGenics, Inc. has announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study assessing lorigerlimab in patients with gynecologic cancers. The study aims to enroll up to approximately 60 participants who have platinum-resistant ovarian cancer or clear cell gynecologic cancer. New participants will be enrolled under a revised protocol with additional risk mitigation for potential toxicities. The company continues to prepare for a mid-2026 program update regarding this clinical trial.
Read more →MGNXMacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Loriger
MacroGenics reported its 2025 financial results, revealing a cash balance of $189.9 million which supports operating activities into late 2027. The company outlined key upcoming data disclosures, including initial results from Phase 1 trials of MGC026 and MGC028 expected in mid-2026 and the second half of 2026, respectively. Additionally, there is an IND submission planned for MGC030 in Q3 2026. However, the company is currently facing a partial clinical hold on its LINNET study, which is under review by the FDA.
Read more →MGNXMacroGenics to Participate in Upcoming March 2026 Investor Conferences
MacroGenics, Inc. has announced its participation in several investor conferences scheduled for March 2026. The company's management team will present, and webcasts of these presentations will be available on their website. This initiative reflects MacroGenics' focus on engaging with investors and promoting its innovative antibody-based therapeutics for cancer treatment.
Read more →MGNXMacroGenics to Participate in Upcoming Investor Conferences
MacroGenics, Inc. has announced its participation in several upcoming investor conferences throughout March 2026, including events in Boston and Miami. CEO Eric Risser will engage in hybrid presentations and fireside chats designed to connect with investors. The conferences are an opportunity for MacroGenics to showcase its innovative antibody-based therapeutics and strengthen relationships within the investor community. Webcasts of these presentations will be available for public access on the company's website.
Read more →MGNXMacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
MacroGenics has announced a partial clinical hold on its Phase 2 LINNET study of lorigerlimab due to safety concerns. The FDA's action follows reports of serious adverse events among participants, including Grade 4 thrombocytopenia and myocarditis. While new patient enrollment is halted, existing participants may continue treatment. The company is working closely with the FDA to lift the hold.
Read more →MGNX301-251-5172 info macrogenics.com Argot Partners 1-212-600-1902 macrogenics argotpartners.com
MacroGenics, Inc. announced a partial clinical hold by the FDA on its LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4 in gynecologic cancers. The hold was prompted by recent severe safety events involving study participants, including Grade 4 adverse effects. While current participants may continue treatment, no new enrollments will occur until the hold is lifted. MacroGenics expressed its commitment to patient safety and intends to work with the FDA to resolve the issue promptly.
Read more →MGNXMacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
MacroGenics, Inc. announced its participation in the 8th Annual Evercore Healthcare Conference, scheduled for December 4, 2025, in Miami, FL. Eric Risser, the President and CEO, will lead a fireside chat at the event starting at 7:55 am ET. This appearance will be accessible via a webcast on the company's Investor Relations page, ensuring that interested parties can follow the discussion. MacroGenics aims to continue showcasing its innovative cancer therapies at major industry events.
Read more →MGNXMacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
MacroGenics reported its third quarter 2025 financial results, highlighting a $75 million non-dilutive partnership payment. The company has decided to halt development of lorigerlimab for prostate cancer but will continue its exploration in ovarian and gynecologic cancers. Additionally, MacroGenics is advancing its ADC programs and has initiated Phase 1 expansion cohorts for MGC026.
Read more →MGNXMacroGenics to Participate in the Stifel 2025 Healthcare Conference
MacroGenics, Inc. announced its participation in the Stifel 2025 Healthcare Conference, where CEO Eric Risser will engage in a fireside chat. The event is scheduled for November 13, 2025, in New York City. A webcast of the presentation will be available on the company's website, with an archived replay for 30 days.
Read more →MGNXMacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference
MacroGenics, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. CEO Eric Risser will lead the presentation, which will focus on the company's innovative antibody-based therapeutics for cancer treatment. A webcast of the event will be available on their website.
Read more →MGNXMacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities
MacroGenics reported its second quarter 2025 financial results, highlighting its strategic priorities for the future. The company is focusing on advancing its pipeline of antibody-based therapeutics, including promising bispecific and antibody-drug conjugate programs. Eric Risser has been appointed as the new CEO, succeeding Scott Koenig, and aims to enhance the company's capital efficiency and focus.
Read more →MGNXMacroGenics Appoints Eric Risser as President and Chief Executive Officer
MacroGenics has appointed Eric Risser as President and CEO, effective August 13, 2025. Risser, who has been with the company since 2009 and served as COO since 2022, succeeds Scott Koenig, who led the company for 24 years. Risser aims to enhance the company's focus and efficiency in delivering innovative cancer therapies.
Read more →MGNXDocument MacroGenics Appoints Eric Risser as President and Chief Executive Officer ROCKVILLE, MD
MacroGenics, Inc. has appointed Eric Risser as its new President and CEO, effective August 13, 2025. Risser, who has been with the company since 2009 and served as COO since 2022, aims to enhance the company's focus and efficiency in delivering cancer therapies. He succeeds Scott Koenig, who led the firm for 24 years and is stepping into an advisory role. Risser is expected to leverage his extensive experience in the biotechnology industry to guide MacroGenics in its next phase of growth.
Read more →MGNXMacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
MacroGenics has entered a royalty purchase agreement with Sagard Healthcare Partners, receiving $70 million upfront for a capped royalty interest in ZYNYZ's global net sales. ZYNYZ, a PD-1 inhibitor, is indicated for specific cancer treatments. The agreement allows MacroGenics to maintain other economic interests related to ZYNYZ, supporting its financial stability through 2027.
Read more →MGNXexpressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may
MacroGenics has entered into a royalty purchase agreement with Sagard Healthcare Partners, receiving $70 million upfront for a capped royalty interest in ZYNYZ's future global net sales. This agreement enables MacroGenics to extend its cash runway through the first half of 2027. ZYNYZ, a PD-1 inhibitor, is indicated for various cancers and is currently marketed by Incyte in the U.S. While the deal bolsters MacroGenics financially, it comes with inherent risks related to market acceptance and regulatory approvals for ZYNYZ.
Read more →MGNXMacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
MacroGenics, Inc. will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025. The management team will discuss the company's innovative antibody-based therapeutics for cancer treatment. A webcast of the presentation will be available on the company's website, with an archived replay for 30 days.
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET,
MacroGenics, Inc. has provided an update on its corporate progress and first quarter 2025 financial results. The company has dosed the first patient in the Phase 2 LINNET study of lorigerlimab for ovarian and gynecologic cancers, signaling advances in its clinical pipeline. Additionally, MacroGenics reported a revenue increase to $13.2 million but experienced a net loss of $41 million. The company projects its cash runway will extend into the second half of 2026, supporting ongoing clinical programs.
Read more →MGNXMacroGenics Announces Date of First Quarter 2025 Financial Results
MacroGenics, Inc. announced that it will release its financial results for Q1 2025 on May 13, 2025, after market close. The company will not hold a conference call to discuss these results or corporate progress for the quarter. Future quarterly conference calls may be resumed.
Read more →MGNXMacroGenics to Participate in Upcoming Investor Conference
MacroGenics, Inc. has announced its participation in an upcoming investor conference. The management team will present details about the company's innovative antibody-based therapeutics for cancer treatment. A webcast of the presentation will be available on the company's website, along with an archived replay for 30 days.
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2024 Financial Results Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC Initiating
MacroGenics has provided a corporate update, reporting the completion of enrollment in the LORIKEET Phase 2 study of lorigerlimab in patients with mCRPC. The company has also announced the initiation of a new LINNET Phase 2 study for lorigerlimab in ovarian cancer. Financially, MacroGenics finished 2024 with a cash balance of $201.7 million, a significant revenue increase attributed to milestones from the Incyte agreement. However, the company decided to discontinue the vobra duo program based on the TAMARACK Phase 2 study results, though its pipeline expansion continues with novel therapeutic candidates.
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
MacroGenics, Inc. has announced the release date for its financial results for the fourth quarter and full year of 2024, set for March 20, 2025. Following the results announcement, the company will host a conference call to discuss these results and recent corporate developments. Investors will be able to listen to the call via teleconference or through a webcast on the company's website, with a recorded replay available afterward.
Read more →MGNXMacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results Strengthened financial position resulting from recently announced MARGENZA transaction and previously announced receipt of milestone
MacroGenics has reported a strengthened financial position following the MARGENZA transaction and milestone payments from Incyte, boosting their revenue significantly. The company submitted an IND application for MGC028 and is preparing to initiate further clinical trials. However, the TAMARACK study of vobramitamab duocarmazine has ceased dosing for participants while they continue to be monitored. Despite pausing other development projects, MacroGenics is optimistic about the upcoming data readouts from their clinical portfolio.
Read more →MGNXMacroGenics Announces Leadership Transition Scott Koenig, M.D., Ph.D., to step down as President and CEO Board to initiate search process to identify new CEO ROCKVILLE, MD, OCT. 30, 2024 (GLOBE NEWSWIRE) MacroGenics, Inc
MacroGenics, Inc. announced that Scott Koenig, M.D., Ph.D., will step down as President and CEO early next year. The Board of Directors has engaged Heidrick & Struggles to find a successor and has formed a special committee to manage the leadership transition. Dr. Koenig, a co-founder of the company, highlighted the progress made during his tenure, including several FDA-approved therapeutics. The company emphasizes its readiness for this leadership change, aiming to continue its mission in cancer therapeutics.
Read more →MGNXMacroGenics Announces Leadership Transition
MacroGenics, Inc. announced a leadership transition with Scott Koenig stepping down as President and CEO in early 2025. The Board of Directors is beginning the search for a new CEO, with Heidrick & Struggles assisting in the process. Under Koenig's leadership for 24 years, the company achieved numerous milestones, including several FDA-approved antibody therapeutics. The timing of the transition is deemed favorable, as the company continues to develop a broad portfolio of cancer therapeutics.
Read more →MGNXMacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
MacroGenics, Inc. will release its third-quarter 2024 financial results on November 5, 2024. The company has scheduled a conference call for the same date at 4:30 PM ET to discuss these results and recent corporate developments. Investors can participate by registering in advance and can access a webcast of the call on the company's website. MacroGenics focuses on antibody-based therapeutics for cancer treatment and has numerous strategic collaborations in place.
Read more →MGNXMacroGenics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2024 Deadline to file Lead Plaintiff Motion
MacroGenics, Inc. is facing a class-action lawsuit from investors who claim the company misled them regarding the safety and efficacy of its cancer drug, vobra duo. This lawsuit is related to statements made during the Phase 2 TAMARACK clinical trial. Following initial optimistic safety data, the company reported that five patient deaths occurred during the study, resulting in a drastic decline in MacroGenics' share price. Investors have until September 24, 2024, to file a lead plaintiff motion.
Read more →MGNXMacroGenics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNX
A class action securities lawsuit has been filed against MacroGenics, Inc. for alleged fraud affecting investors between March 7, 2024, and May 9, 2024. The lawsuit claims that the company misrepresented safety data related to its drug vobramitamab duocarmazine, leading to a dramatic 77.4% stock price drop after the facts were revealed. Investors have until September 24, 2024, to request lead plaintiff status in the case. Participation in the lawsuit entails no out-of-pocket costs for class members.
Read more →MGNXMacroGenics Announces Updated Efficacy Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landma
MacroGenics has announced updated efficacy and safety data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The results showed promising antitumor activity, with 6-month radiographic progression-free survival (rPFS) rates at 69% for the 2.0 mg/kg cohort and 70% for the 2.7 mg/kg cohort. However, the study also revealed concerns with treatment-related adverse events, including several fatalities. The company expects to provide mature median rPFS data by early 2025.
Read more →MGNXMACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline
Bernstein Liebhard LLP has reminded investors of MacroGenics, Inc. of an upcoming deadline to file a lead plaintiff motion in a class action lawsuit. This lawsuit alleges that the company made misrepresentations concerning early interim safety data results from its TAMARACK Phase 2 study of the prostate cancer drug vobramitamab duocarmazine. Investors who purchased shares during the defined class period are encouraged to discuss their rights. The deadline to file papers is September 24, 2024.
Read more →MGNXMacroGenics (MGNX) Investors Alerted to September 24th Deadline in Securities Class Action, Encouraged to Contact Hagens Berman
MacroGenics Inc. is facing legal action over allegations that it misled investors about the safety and efficacy of its experimental drug, vobra duo. Following an update from the Phase 2 TAMARACK study, which recommended the discontinuation of additional therapy for vobra duo due to patient safety concerns, the company's shares plummeted by 28%. This followed an earlier increase in share price based on optimistic safety data. The emergence of patient deaths during the study has compounded the impact on the company's stock performance and reputation.
Read more →MGNXMacroGenics (MGNX) Crashed 28% After Pausing Phase 2 TAMARACK Study, Class Action Accuses Company of Misleading Investors Over Cancer Drug Trial – Hagens Berman
MacroGenics Inc. experienced a 28% share price drop after the Phase 2 TAMARACK study on its cancer drug, vobra duo, was paused due to safety recommendations. The decision to halt the study came after interim data revealed an alarming rate of serious side effects, including five patient deaths. In the wake of these events, a class-action lawsuit has been filed against the company, claiming they misled investors about the drug's safety and efficacy. Analyst downgrades have followed the negative news, compounding the ongoing challenges for the firm.
Read more →MGNXMacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics, Inc. has announced that it will present Phase 2 data for vobramitamab duocarmazine at the upcoming ESMO Congress 2024 in Barcelona. The data will focus on the treatment of metastatic castration-resistant prostate cancer and will be available in a poster presentation. The company will also host a conference call on September 16, 2024, to discuss the findings and provide an update on its corporate initiatives.
Read more →MGNXMacroGenics, Inc. (MGNX) Investors: September 24, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
MacroGenics, Inc. is facing a securities class action lawsuit filed in the District Court for Maryland concerning misleading statements related to the safety of its drug vobramitamab duocarmazine. The lawsuit represents investors who purchased stock or sold puts during a specified class period. A lead plaintiff is to be appointed by September 24, 2024. Allegations suggest that the company's communication about the drug's safety profile and Phase 2 study data created a misleading impression among investors.
Read more →MGNXMacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens Berman
MacroGenics, Inc. is facing a class-action lawsuit for allegedly misleading investors regarding its cancer drug vobra duo. The lawsuit claims that the company downplayed safety concerns related to the drug, which showed a higher-than-expected rate of serious side effects during clinical trials. Initially, MacroGenics reported promising results, resulting in a significant share price increase, but the revelation of five patient deaths led to a drastic decline in stock value. This situation has drawn attention from legal firms investigating potential corporate misconduct.
Read more →MGNXMacroGenics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2024 Deadline to file Lead Plaintiff Motion.
MacroGenics, Inc. is facing a class-action lawsuit filed by investors who believe the company misled them about the safety and efficacy of its experimental drug, vobra duo. Investors are urged to file a lead plaintiff motion by September 24, 2024, if they purchased securities between March 7 and May 9, 2024. The lawsuit references concerning interim safety data from the TAMARACK clinical trial, which showed serious side effects and coincided with patient deaths, causing a significant drop in the company’s stock price. The Portnoy Law Firm is assisting affected investors in this matter.
Read more →MGNXMacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX
MacroGenics, Inc. is facing a class action lawsuit related to alleged securities fraud due to misinformation about the safety data of its drug, vobramitamab duocarmazine. During a specific class period in 2024, it was revealed that the drug posed greater risks than previously communicated, leading to a drastic decline in the company's stock value. Shareholders are encouraged to participate in the lawsuit, with a deadline for lead plaintiff registration set for September 24, 2024.
Read more →MGNXMacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis – Hagens Berman
MacroGenics, Inc. (MGNX) is facing significant challenges following a downgrade from financial blogger Myriam Alvarez, who issued a 'strong sell' rating after disappointing trial results for its prostate cancer drug candidate, Vobra Duo. The company's share price has sharply declined after the July announcement of a halted mid-stage clinical trial, coinciding with the launch of a class-action lawsuit by investors regarding misleading statements about the drug's safety. In light of five patient deaths disclosed on May 10, a prominent litigation firm is investigating the company for potential securities law violations.
Read more →MGNXMacroGenics, Inc. Class Action: Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 – MGNX
MacroGenics, Inc. is currently facing a class action securities lawsuit due to alleged fraud related to safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. The lawsuit affects investors who suffered losses between March 7, 2024, and May 9, 2024. Following the disclosure that the drug was more dangerous than previously stated, MacroGenics' stock plummeted by 77.4%. Investors looking to participate in the lawsuit must act before the deadline of September 24, 2024.
Read more →MGNXMacroGenics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights – MGNX
MacroGenics, Inc. is embroiled in a class action lawsuit due to alleged securities fraud related to misleading safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. The lawsuit affects investors who experienced losses between March 7, 2024 and May 9, 2024. Following the disclosure of the drug's serious risks on May 9, 2024, the company's stock plummeted 77.4%. Investors have until September 24, 2024, to seek appointment as lead plaintiff.
Read more →MGNXMacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit – Hagens Berman
MacroGenics, Inc. has suspended its Phase 2 clinical trial for the prostate cancer drug vobra duo due to fatal adverse events involving five patients. This decision followed the disclosure of the deaths, which led to a dramatic drop in the company’s share price by about 77%. Additionally, the company is facing a class action lawsuit alleging it misled investors regarding the drug's safety. Despite these setbacks, MacroGenics plans to present further data at an upcoming medical conference.
Read more →MGNXMacroGenics, Inc. Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against MGNX
A class action lawsuit has been filed against MacroGenics, Inc. on behalf of investors who acquired shares between March 7, 2024, and May 9, 2024. The suit alleges that the company made misleading statements regarding the efficacy of its drug candidate, vobramitamab duocarmazine, during the TAMARACK Phase 2 study while obscuring negative interim safety data. Following the disclosure of adverse outcomes related to the drug, the company's stock plummeted by over 77%. Investors must file their motions by September 24, 2024, to be considered for lead plaintiff roles.
Read more →MGNXMacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in September Received $100.0 million in
MacroGenics provided a corporate update highlighting the upcoming poster presentation of the TAMARACK Phase 2 study data at the ESMO Congress. The company successfully received $100 million in milestone payments from Incyte due to advancements in the development of ZYNYZ. Despite these positives, MacroGenics reported a net loss of $55.7 million and decreased revenue for the second quarter of 2024. They confirmed their cash position should sustain operations into 2026, bolstered by projected future payments from collaborations and product revenues.
Read more →MGNXMacroGenics (MGNX) Faces Class Action After Revealing Investigation of Patient Deaths in TAMARACK Study of Vobra Duo – Hagens Berman
MacroGenics, Inc. is facing a class-action lawsuit following the deaths of five patients during its TAMARACK study involving the antibody-drug conjugate MGC018. Initially, positive interim safety data had increased investor confidence, leading to a significant rise in the company’s stock price. However, the subsequent announcement of patient deaths resulted in a drastic reduction of approximately 77% in share value. Analysts have expressed concerns regarding the safety and tolerability of the drug based on discrepancies between the reported interim data and the outcomes observed.
Read more →MGNXMacroGenics (MGNX) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action
Johnson Fistel, LLP has initiated a class action lawsuit on behalf of MacroGenics shareholders who experienced significant losses between March 7, 2024, and May 9, 2024. The lawsuit alleges that MacroGenics issued false and misleading statements while concealing adverse facts about early safety data from the TAMARACK Phase 2 clinical study. Shareholders are urged to act by September 24, 2024, to establish themselves as lead plaintiffs in the case. The allegations stemmed from the company's presentation of interim safety and efficacy data for its cancer treatment, which led to investor claims of misrepresentation.
Read more →MGNXMACROGENICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MacroGenics, Inc. - MGNX
ClaimsFiler has notified MacroGenics shareholders about a class action lawsuit, reminding them that they can file lead plaintiff applications by September 24, 2024. The lawsuit stems from allegations that MacroGenics and its executives failed to disclose critical information regarding patient deaths during a clinical trial for their cancer drug, vobra duo. Following the disclosure of the deaths, MacroGenics' stock saw a significant drop in value. Investors who purchased shares during the class period from March 7, 2024, to May 9, 2024, may be eligible to participate in the lawsuit.
Read more →MGNXMACROGENICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against MacroGenics, Inc. due to allegations of misleading investors about the safety data from its TAMARACK Phase 2 trial of vobramitamab duocarmazine. This follows the revelation of five fatalities associated with the treatment, which led to a drastic 77.4% drop in share price. Affected investors are encouraged to contact the law firm Bragar Eagel & Squire for more information. The lawsuit covers securities purchased or acquired between March 7 and May 9, 2024.
Read more →MGNXstatements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking stateme
MacroGenics announced an update on its TAMARACK Phase 2 study of vobramitamab duocarmazine, set for presentation at the ESMO Congress 2024. The poster will provide insights on the study's primary endpoint of 6-month radiographic progression-free survival and updated safety data. Following an independent review, treatment has been discontinued for some participants due to safety and efficacy assessments. The company plans to host an investor call after the ESMO presentation to discuss findings and potential next steps for the vobra duo program.
Read more →MGNXthe regulatory review process expectations for regulatory approvals expectations of future milestone payments the impact of competitive products our ability to enter into agreements with strategic partners and other matt
MacroGenics announced the achievement of $100 million in milestone payments from Incyte Corporation related to their collaboration on retifanlimab, also known as ZYNYZ. The successful development progress of this PD-1 inhibitor positions MacroGenics for additional milestone payments, with the potential to receive up to $210 million in future milestones. With this funding, the company's cash runway is expected to last into 2026, reflecting a positive outlook on their ongoing operational and clinical activities.
Read more →MGNXMacroGenics Provides Vobramitamab Duocarmazine Update
MacroGenics provided an update on its vobramitamab duocarmazine program ahead of the ESMO Congress 2024, where new clinical data from the TAMARACK Phase 2 study will be showcased. The company has reported successfully reaching the study's primary endpoint of 6-month radiographic progression-free survival (rPFS) but decided to discontinue additional dosing for participants due to emerging adverse events. The updated data will include safety and efficacy insights, and the company plans to hold an investor call to discuss potential next steps post-ESMO presentation.
Read more →MGNXMacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
MacroGenics, Inc. has announced the achievement of $100 million in milestone payments from Incyte Corporation related to their collaboration on the development of the PD-1 inhibitor ZYNYZ (retifanlimab-dlwr). This milestone is part of a broader licensing agreement originally established in 2017, under which MacroGenics could potentially receive up to $210 million in development milestones and $330 million in commercial milestones. The company believes its current financial resources, along with anticipated future payments, will support operations through 2026. The continued development by Incyte of retifanlimab for various cancer indications represents an optimistic outlook for future profitability.
Read more →MGNXMacroGenics ALERT: Securities Fraud Lawsuit Could Allow Investors to Recover Losses; Block & Leviton Encourages Investors to Contact the Firm to Learn More
A securities fraud lawsuit has been initiated against MacroGenics, Inc., claiming that the company and its executives misrepresented safety data related to vobramitamab duocarmazine. The lawsuit comes after the revelation that the drug posed greater risks than previously disclosed, resulting in a significant stock price decline of 77%. Affected investors are encouraged to contact Block & Leviton to explore potential recovery of losses. The deadline to seek lead plaintiff status is September 24, 2024.
Read more →MGNXMACROGENICS, INC. (NASDAQ: MGNX) INVESTOR ALERT: Investors With Large Losses in MacroGenics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A class action lawsuit has been filed against MacroGenics, Inc. on behalf of investors who purchased the company's stock between March 7 and May 9, 2024. The lawsuit claims that MacroGenics made misleading statements regarding safety data from its TAMARACK Phase 2 study for the prostate cancer drug vobramitamab duocarmazine. Investors wishing to participate must do so by September 24, 2024, with no fees required upfront as all representation is handled on a contingency basis.
Read more →MGNXMacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash – Hagens Berman
MacroGenics, Inc. (MGNX) is under investigation regarding the integrity of its safety data from the Phase 2 TAMARACK study of vobra duo, following the announcement of five patient deaths. Initially, positive results from interim safety data had boosted stock prices, but following the deaths disclosed on May 10, 2024, the shares plummeted by about 77%. The company has acknowledged that it is probing the circumstances surrounding the deaths of three patients. Moreover, analysts have downgraded the stock due to concerns over the new safety data potentially conflicting with earlier reports.
Read more →MGNXMacroGenics, Inc. Investors: Company Investigated by the Portnoy Law Firm
MacroGenics, Inc. is under investigation by the Portnoy Law Firm for potential securities fraud, following significant losses suffered by investors. The law firm is considering filing a class action on behalf of affected shareholders. A recent announcement indicated serious safety concerns related to its Phase 2 TAMARACK study, highlighted by the unfortunate deaths of five patients. This news contributed to a drastic decrease in the company's stock price, which fell by 77.4% on May 10, 2024.
Read more →MGNXMacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman
MacroGenics, Inc. has faced significant backlash after reporting five patient deaths in its Phase 2 TAMARACK study of MGC018, an antibody-drug conjugate for metastatic castration-resistant prostate cancer. Although the company initially reported promising interim safety data, the revelation of patient deaths led to a drastic 77% drop in stock prices and multiple analyst downgrades. Hagens Berman is investigating potential misleading statements regarding the safety data, as the recent findings contradicted earlier reports.
Read more →MGNXMACROGENICS ALERT: Bragar Eagel & Squire, P.C. is Investigating MacroGenics, Inc. on Behalf of MacroGenics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation into MacroGenics, Inc. on behalf of its stockholders. This investigation is related to potential claims of violations of federal securities laws and other unlawful business practices. Recently, MacroGenics disclosed that five patients died during its TAMARACK clinical trial, which led to a drastic drop in its stock price, falling over 70%. The law firm is encouraging investors who believe they have suffered losses to come forward and participate in the action.
Read more →MGNXMacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data Presentation of interim TAMARACK Phase 2 study data updated safety and preliminary efficacy
MacroGenics has provided an update on its corporate progress alongside financial results for Q1 2024, highlighting promising interim data from the TAMARACK Phase 2 study of vobra duo in metastatic castration-resistant prostate cancer (mCRPC). The study shows encouraging safety and preliminary efficacy data, reinforcing MacroGenics' belief in the therapy's potential. A Phase 3 study is being planned based on this interim data, with anticipation for final comprehensive results to be shared later in 2024. Additionally, MacroGenics aims to broaden the study to include other cancer types.
Read more →MGNXMacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
MacroGenics, Inc. announced it will release its first-quarter financial results for 2024 on May 9, 2024, after market close. The company will host a conference call at 4:30 pm ET to discuss these results and recent corporate developments. The company focuses on developing innovative monoclonal antibody-based therapeutics for cancer treatment, supported by advanced technology platforms. Investors can participate in the call via registration and can access a webcast of the discussion.
Read more →MGNXclinical trials, expected timing of results from clinical trials, discussions with regulatory agencies, commercial prospects of or product revenues from MARGENZA and the Company's product candidates, if approved, manufac
MacroGenics, Inc. provided early interim safety data from its Phase 2 TAMARACK study on vobramitamab duocarmazine (vobra duo) for treating metastatic castration-resistant prostate cancer. Although the submitted abstract for presentation at the ASCO meeting was not accepted, the company plans to disclose updated interim data, including safety and preliminary efficacy, by May 31, 2024. The study is currently ongoing with a focus on dose levels and aims to assess the treatment's effectiveness and tolerability. Preliminary data indicates that dosage reduction may enhance overall safety outcomes for patients.
Read more →MGNXMacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
MacroGenics announced early interim safety data from its Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for treating metastatic castration-resistant prostate cancer. While the submitted abstract for the study was not accepted for presentation at the ASCO Annual Meeting, the company plans to provide updated safety and efficacy data by May 31, 2024. Further clinical data, including radiographic progression-free survival, is expected to be shared in Fall 2024. The study currently shows improved tolerability with reduced dosing in comparison to earlier trials.
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2023 Financial Results Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024 Initiation of Phase 1 study o
MacroGenics provided an update on its corporate progress and financial results for 2023. The company reported the successful enrollment of 177 patients in the TAMARACK Phase 2 study of vobra duo, with preliminary data expected to be presented at ASCO 2024. Additionally, MacroGenics has initiated a Phase 1 study of MGC026 and reported a decrease in total revenue alongside a significant net loss. Nonetheless, the company remains optimistic about its pipeline advancements and prospects for 2024.
Read more →MGNXMacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. has announced the date for its fourth quarter 2023 financial results, which will be released on March 7, 2024. Following the results, the company will host a conference call at 4:30 pm ET to discuss its financial performance and recent corporate developments. Investors can register to participate via telephone or listen to a webcast on the company's Investor Relations website. A recorded replay will be available shortly after the call for those unable to attend.
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule Initiated LORIKEET Phase 2 study of lorigerlimab Su
MacroGenics has announced significant corporate progress and financial results for Q3 2023, highlighting the successful early completion of the TAMARACK Phase 2 study enrollment for vobra duo. The company also initiated the LORIKEET Phase 2 study for lorigerlimab, underscoring its active clinical pipeline. Financially, MacroGenics reported $10.4 million in revenue for the quarter and a cash balance of $256.4 million, extending its cash runway into 2026. The company plans to provide updates on several studies and has received a notable milestone payment from Gilead for its bispecific antibody program.
Read more →MGNXMacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. will release its financial results for the third quarter of 2023 on November 6, 2023, after market close. The company will also host a conference call at 4:30 pm ET on the same day to discuss these results and recent corporate progress. Investors can participate by registering in advance or accessing a live webcast through the company's Investor Relations page. MacroGenics specializes in the development of antibody-based therapeutics for cancer treatment.
Read more →MGNXMacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
MacroGenics, Inc. announced the achievement of a $15 million milestone following Gilead Sciences' nomination of a bispecific research program. This partnership revolves around MacroGenics’ proprietary DART and TRIDENT platforms. Under the existing agreement, besides the milestone fee, MacroGenics stands to gain up to $1.7 billion in various additional payments. The milestone is linked to the investigational bispecific antibody, MGD024, aimed at treating cancer.
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol
MacroGenics provided an update on its corporate progress and financial results for Q2 2023, highlighting advancements in its TAMARACK Phase 2 study for metastatic castration-resistant prostate cancer (mCRPC) under a revised protocol. The company is also initiating a Phase 2 study for lorigerlimab in mCRPC patients and reported a $50 million milestone payment from Sanofi due to positive study results for TZIELD. Moreover, its cash position improved significantly, leading to a net income of $57.5 million for the quarter, compared to a loss in the previous year.
Read more →MGNXMacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. announced that it will release its second quarter 2023 financial results on August 9, 2023, after market close. Following the release, a conference call will take place at 4:30 pm ET to discuss the financial results and recent corporate developments. Participants can register in advance for the call and access a listen-only webcast on the company's website. This information reflects MacroGenics' commitment to transparency and investor relations.
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results ZYNYZ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metasta
MacroGenics, Inc. provided a corporate update and first quarter 2023 financial results, highlighting the FDA approval of ZYNYZ, its third product originating from its pipeline. The company reported a cash balance of $241.7 million, which, along with projected revenues from collaborations, supports operations through 2025. Multiple Phase 2 clinical trials of investigational products, including vobramitamab duocarmazine and lorigerlimab, continue advancing. Despite achieving non-dilutive funding of $270 million, MacroGenics reported a net loss of $38 million for the quarter.
Read more →MGNXMacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. has announced the release of its financial results for the first quarter of 2023, scheduled for May 9, 2023. Following the results announcement, a conference call will take place at 4:30 PM ET to discuss these results and recent corporate developments. Participants can join the call by registering in advance, and a recorded version of the webcast will be made available shortly after the call concludes, remaining accessible for 30 days.
Read more →MGNXMacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ (retifanlimab-dlwr) Rockville, MD.
MacroGenics announced it will receive a $15 million milestone payment following the U.S. FDA's approval of ZYNYZ (retifanlimab-dlwr). This humanized monoclonal antibody targets PD-1 and is aimed at treating Merkel cell carcinoma. The approval represents a significant achievement, being the third product approved from MacroGenics' portfolio since the company's inception. Incyte, the partner in this project, is expected to further develop ZYNYZ for additional indications and markets.
Read more →MGNXMacroGenics Provides Corporate Update and 2022 Financial Results Cash runway extended through 2025 with $250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of acceler
MacroGenics has provided a corporate update and reported financial results for 2022. The company successfully extended its cash runway through 2025 with $250 million in non-dilutive funding. Notably, clinical data for lorigerlimab in metastatic castration-resistant prostate cancer showed promising results. Additionally, modifications to the TAMARACK study design aim to expedite progress for its vobramitamab duocarmazine candidate.
Read more →MGNXMacroGenics Announces Sale of TZIELD Royalty Interest for up to $200 Million Rockville, Md.
MacroGenics, Inc. has entered into a sale agreement for its royalty interest on future global net sales of its product TZIELD, receiving up to $200 million from DRI Healthcare Trust. The deal includes a $100 million upfront payment and allows MacroGenics to share in additional revenues depending on TZIELD's performance in the market. The company keeps other economic interests tied to the product, maintaining a financial stake in its potential success.
Read more →MGNXMacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. plans to release its fourth quarter 2022 financial results on March 15, 2023, after market close. A conference call is scheduled for the same day at 4:30 pm ET to discuss these results alongside recent corporate developments. The company specializes in monoclonal antibody therapeutics for cancer treatment, leveraging advanced technology platforms for product development.
Read more →MGNXMacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium Twelve of
MacroGenics has announced promising preliminary clinical results for lorigerlimab in patients with metastatic castration-resistant prostate cancer (mCRPC). In a single-arm study, 28.6% of patients achieved a 50% reduction in prostate-specific antigen (PSA) levels, while 25.7% achieved confirmed partial responses. The safety profile was found to be manageable with no fatalities directly linked to the treatment. Following these results, the company plans to move forward with a Phase 2 study of lorigerlimab later this year.
Read more →MGNXMacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors ROCKVILLE, MD
MacroGenics has appointed Dr. Margaret Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu, an expert in gene therapy and immunotherapy, will join the Science and Technology Committee, while Ms. Chhabra Karson will serve on the Audit Committee. Both appointments are aimed at leveraging their extensive industry knowledge to enhance the company's mission in developing groundbreaking cancer therapies. The Board now consists of ten directors, with the majority being independent.
Read more →MGNXMacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
MacroGenics, Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference. The company's President & CEO, Scott Koenig, M.D., Ph.D., will deliver a business update on January 12, 2023. This participation seeks to enhance company visibility among investors and industry stakeholders. The event underscores MacroGenics' dedication to advancing its innovative antibody-based therapeutics in cancer treatment.
Read more →MGNXMacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab ROCKVILLE, M D.
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab ROCKVILLE, MD., November 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th
Read more →MGNXMacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMAR
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results Collaboration with Gilead to develop bispecific antibodies, including MGD024, announced Planned initiation of Phase 2 portion of MGC018 TAMARACK study in prostate cancer by year-end Anticipated upda
Read more →MGNXMacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release i
Read more →MGNXGilead Contacts MacroGenics Contact Jacquie Ross, Investors Jim Karrels, Senior Vice President, CFO investor_relations gilead.com info macrogenics.com Marian Cutler, Media Marian.Cutler1 gilead.com GILEAD AND MACROGENICS
Gilead Contacts MacroGenics Contact Jacquie Ross, Investors Jim Karrels, Senior Vice President, CFO investor_relations gilead.com info macrogenics.com Marian Cutler, Media Marian.Cutler1 gilead.com GILEAD AND MACROGENICS ANNOUNCE ONCOLOGY COLLABORATION TO DEVELOP BISPECIFIC
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2 3 stud
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignancies Plan to initiate MGC018 Phase 2 3 study in prostate cancer by year-end Initiates cost-saving me
Read more →MGNXMacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release it
Read more →MGNXMacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer ROCKVILLE, MD
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a biopharmaceutical company focused on developing and commercializing
Read more →MGNXMacroGenics Announces Appointment of William Heiden to Board of Directors ROCKVILLE, MD
MacroGenics Announces Appointment of William Heiden to Board of Directors ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatme
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results Plan to start Phase 2 3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorig
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results Plan to start Phase 2 3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors Targeting mid-2022 start
Read more →MGNXMacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release i
Read more →MGNXMacroGenics Announces Executive Promotion
ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief O
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2021 Financial Results Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks Prioritizing MGD024 as le
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks Prioritizing MGD024 as lead CD3-based DART molecule targeting CD123 and discontinui
Read more →MGNXMacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release it
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results Investigational New Drug (IND) application submitted for MGD024, a next generation DART molecule targeting CD123 and CD3 for AML
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results Investigational New Drug (IND) application submitted for MGD024, a next generation DART molecule targeting CD123 and CD3 for AML U.S. Food Drug Administration (FDA) approves MacroGenics'
Read more →MGNXMacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release it
Read more →MGNXMacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A 78% of patients had tumor shrinkage at first scan Median duration of response was 10.3 months as of data c
Read more →MGNXMacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presented at ESMO 2021 Virtual Annual Congress
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen (PSA) reduction; 10 of 16 (63%) RECIST-evaluable patients had anti-tumor activity; 4 of 16 (25%) achieved partial responses (two confirmed and two unconfirmed
Read more →MGNXMacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating t
Read more →MGNXMacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer
Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting Co
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting Conference call scheduled for today at 4 30 p.m. ET. ROCKVI
Read more →MGNXMacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, July 22, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release i
Read more →MGNXMacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms and a lead research program targeting solid tumors Zai Lab provides
Read more →MGNXMacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patients Cohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction; anti-tumor activity observed in four of seven patients evaluated (including one un
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results MARGENZA launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO Conference call sched
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results MARGENZA launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO Conference call scheduled for today at 4 30 p.m. ET. ROCKVILLE, MD., April 29
Read more →MGNXMacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
ROCKVILLE, MD, April 19, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release
Read more →MGNXMacroGenics Announces Presentations at the 2021 AACR Annual Meeting
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the American A
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2020 Financial Results - MARGENZA approved in December 2020 commercial launch expected March 2021 - July 2021 PDUFA target action dates for partnered products retifan
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results -MARGENZA approved in December 2020 commercial launch expected March 2021 -July 2021 PDUFA target action dates for partnered products retifanlimab and teplizumab -Multiple clinical updates across port
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
ROCKVILLE, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release i
Read more →MGNXMacroGenics Names Federica O’Brien to its Board of Directors
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Fr
Read more →MGNXMacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone ha
Read more →MGNXCautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, cli
MacroGenics Names Federica O'Brien to its Board of Directors ROCKVILLE, MD, Feb 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment
Read more →MGNXMacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with chemotherapy In the U.S., MARGENZA is approved, in combination with chemotherapy, for the
Read more →MGNXMacroGenics Announces MGD019 Publication in Cell Reports Medicine
ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript
Read more →MGNXMacroGenics Enters Research Collaboration with Janssen to Develop Novel DART Molecule
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and gl
Read more →MGNXMacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for
Read more →MGNXMacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
53.8% ORR in relapsed/refractory DLBCL patients Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date ROCKVILLE, MD, Dec. 07, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceut
Read more →MGNXMacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patients Median duration of response = 8.13 months ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and
Read more →MGNXMacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses EVERSANA may earn revenue share payments over five years subject to predefined cap MacroGenics’ projected cash runway remains into 2023 ROCKVILLE, MD and CHICAGO, IL, Nov. 3
Read more →MGNXMacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that $25 million in
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results - Conference call scheduled for today at 4 30 p.m.
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results -Conference call scheduled for today at 4 30 p.m. ET. ROCKVILLE, MD., November 4, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical company focu
Read more →MGNXMacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced six clinical and prec
Read more →MGNXMacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wil
Read more →MGNXMacroGenics Announces Flotetuzumab Publication in Blood Advances
ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a
Read more →MGNXMacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
Manuscript describes preclinical development of MGC018 Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage bio
Read more →MGNXMacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of
Read more →MGNXMacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal a
Read more →MGNXMacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibition Recommended Phase 2 dose established for MSS CRC, NSCLC expansion cohorts Presentation is available on-demand as part of the ESMO Virtual Congress 202
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results - Conference call scheduled for today at 4 30 p.m.
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results -Conference call scheduled for today at 4 30 p.m. ET. ROCKVILLE, MD., July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical company focuse
Read more →MGNXMacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call
Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wil
Read more →MGNXMacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Lancet Oncology
Read more →MGNXMacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
Rockville, MD, June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentations at the
Read more →MGNXMacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer Rockville, MD
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer Rockville, MD, June 16, 2020 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for t
Read more →MGNXMacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food a
Read more →MGNXMacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia
Rockville, MD, June 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced research published i
Read more →MGNXMacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer
- Advisory committee meeting not required; PDUFA goal date unchanged Rockville, MD, May 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeut
Read more →MGNXMacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
Rockville, MD, May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical
Read more →MGNXMacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO
Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a confer
Read more →MGNXMacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results f
Read more →MGNXDocument MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting Rockville, MD
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing i
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results - Conference call scheduled for today at 4 30 p.m.
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results -Conference call scheduled for today at 4 30 p.m. ET. ROCKVILLE, MD., May 5, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical company focused o
Read more →MGNXMacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
Rockville, MD, April 29, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced three clinical pres
Read more →MGNXDocument MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format Rockville, MD
MacroGenics to Host its Annual Meeting of Stockholders in Virtual Format Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based thera
Read more →MGNXMacroGenics to Host its Annual Meeting of Stockholders in Virtual Format
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that its 2020 Annua
Read more →MGNXMacroGenics Announces Date of First Quarter 2020 Financial Results Conference Call
Rockville, MD, April 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wi
Read more →MGNXMacroGenics Announces Presentation of Flotetuzumab Translational Data at the 2020 AACR Annual Meeting
Rockville, MD, April 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced data related to flo
Read more →MGNXMacroGenics Announces Departure of Chief Medical Officer ROCKVILLE, MD
MacroGenics Announces Departure of Chief Medical Officer ROCKVILLE, MD, March 4, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the
Read more →MGNXAbout MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates
MacroGenics Provides Update on Corporate Progress and 2019 Financial Results -Margetuximab BLA for metastatic HER2-positive breast cancer accepted for review by the FDA Phase 2 3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancer -First clinical data fro
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2019 Financial Results
Margetuximab: BLA for metastatic HER2-positive breast cancer accepted for review by the FDA; Phase 2/3 MAHOGANY study ongoing in front-line advanced HER2-positive gastric cancer First clinical data from Phase 1/2 studies of MGD013, MGC018 and MGD019 anticipated in 2020 Conferen
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call
Rockville, MD, Feb. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wil
Read more →MGNXMacroGenics to Present at the J.P. Morgan Healthcare Conference
Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wil
Read more →MGNXMacroGenics Outlines Corporate Priorities for 2020
Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced its corporate and pr
Read more →MGNXMacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA
ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has
Read more →MGNXMacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from
Read more →MGNXMacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from
Read more →MGNXMacroGenics to Participate in the Evercore ISI HealthCONx Conference
Rockville, MD, Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXwww.macrogenics.com. MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about futur
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results Conference call scheduled for today at 4 30 p.m. ET ROCKVILLE, MD., November 6, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical company focuse
Read more →MGNXMacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019
ROCKVILLE, MD, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the clinical and pre
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corp
Read more →MGNXMacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call
Rockville, MD, Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wil
Read more →MGNXMacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
Rockville, MD, Oct. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patie
Read more →MGNXDocument Exhbit 99.1 MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer ROCKVILLE, MD
MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer ROCKVILLE, MD, October 22, 2019 (GLOBE NEWSWIRE) - MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical com
Read more →MGNXMacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
ROCKVILLE, MD, Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced topline results from
Read more →MGNXMacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress
ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from
Read more →MGNXMacroGenics to Participate in Cantor Global Healthcare Conference
ROCKVILLE, MD, Sept. 26, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's
Read more →MGNXMacroGenics, Inc. Shareholder Alert – Kehoe Law Firm, P.C. Investigating Claims on Behalf of MacroGenics Investors – MGNX
PHILADELPHIA, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. announces that a class action lawsuit has been filed in United States District Court on behalf of purchasers of the common stock of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX) during the p
Read more →MGNXthereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results Conference call scheduled for today at 4 30 p.m. ET ROCKVILLE, Md., July 31, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ MGNX), a clinical-stage biopharmaceutical company focused
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results
ROCKVILLE, Md., July 31, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corp
Read more →MGNXMacroGenics Announces Date of Second Quarter 2019 Financial Results Conference Call
Rockville, Md., July 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wi
Read more →MGNXMacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
Enrollment of Phase 1 monotherapy expansion cohort completed; presentation of data expected 2H2019 End of Phase 1 meeting requested with FDA to discuss program and future development plans Initiation of enrollment of combination study with anti-PD-1 is imminent MacroGenics wil
Read more →MGNXMacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, and I-Mab Biopha
Read more →MGNXMacroGenics to Participate in Jefferies Healthcare Conference
Rockville, MD, May 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's ma
Read more →MGNXMacroGenics to Host Conference Call and Webcast to Review Margetuximab Phase 3 SOPHIA Study Presentation at ASCO
Rockville, MD, May 28, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a confere
Read more →MGNXMacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy) Oral abstract will be presented at American Society of Clinical Oncology (ASCO) Annual Meeting on June 4, 2019 at 9:45 a.
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
ROCKVILLE, Md., May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corpo
Read more →MGNXMacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call
ROCKVILLE, MD, April 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company wi
Read more →MGNXMacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019
ROCKVILLE, MD, April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the presentation of
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2018 Financial Results
Margetuximab: Positive Phase 3 SOPHIA study with BLA submission planned for second half of 2019; Plans to initiate Phase 2/3 registration-directed, front-line gastric cancer study Enoblituzumab: Encouraging anti-PD-1 combo data supports Phase 2 study initiation in second half of
Read more →MGNXDocument Exhibi t 99.1 MacroGenics Provides Update on Corporate Progress and 2018 Financial Results Margetuximab Positive Phase 3 SOPHIA study with BLA submission planned for second half of 2019 Plans to initiate Phase 2
MacroGenics Provides Update on Corporate Progress and 2018 Financial Results Margetuximab Positive Phase 3 SOPHIA study with BLA submission planned for second half of 2019 Plans to initiate Phase 2 3 registration-directed, front-line gastric cancer study Enoblituzumab Encouragi
Read more →MGNXMacroGenics Announces Participation in SVB Leerink Global Healthcare Conference
ROCKVILLE, MD, Feb. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2018 Financial Results Conference Call
ROCKVILLE, MD, Feb. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on Tuesday, Feb
Read more →MGNXMacroGenics Announces Pricing of Public Offering of Common Stock
ROCKVILLE, MD, Feb. 12, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an un
Read more →MGNXMacroGenics to Participate in Guggenheim Healthcare Talks Idea Forum
ROCKVILLE, MD, Feb. 13, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXMacroGenics Announces Proposed Public Offering of Common Stock
ROCKVILLE, MD, Feb. 12, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commence
Read more →MGNXMacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab
Margetuximab improved progression-free survival (PFS) compared to HERCEPTIN® (trastuzumab), when used in combination with chemotherapy in patients with HER2+ metastatic breast cancer BLA submission targeted for second half of 2019 Company to host conference call today at 8:30 A
Read more →MGNXMacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA
ROCKVILLE, MD, Jan. 25, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food an
Read more →MGNXMacroGenics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Rockville, MD, Jan. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M
Read more →MGNXMacroGenics Announces Partial Clinical Hold on MGD009 Phase 1 Studies
ROCKVILLE, MD, Dec. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on December 6,
Read more →MGNXMacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing development Expand Zai Lab’s late-stage clinical pipeline with margetuximab and obtain rights to first-in-class dual checkpoint inhibitor, MGD013 Jointly conduct global stud
Read more →MGNXMacroGenics Announces Participation in Three Investor Conferences
ROCKVILLE, MD, Nov. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXMacroGenics Announces Poster Presentation on Preclinical PD-L1 x CD137 DART Program at the EORTC-NCI-AACR Symposium in Dublin
ROCKVILLE, MD, Nov. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it had presente
Read more →MGNXMacroGenics Reports Presentation of Clinical Data at 33rd Annual SITC Meeting
Enoblituzumab + pembrolizumab combination study data reported: ORRs in anti-PD-1/PD-L1 naïve SCCHN and NSCLC cohorts benchmarked favorably vs. approved anti-PD-1 agents Interim data from Phase 1 dose expansion study of MGA012 (anti-PD-1): objective responses in NSCLC, cervical c
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 3rd Quarter 2018 Financial Results
Margetuximab: Phase 3 SOPHIA study enrollment completed; topline results 1Q 2019 PD-1 franchise: MGD013 cohort expansions initiated; $15 million in MGA012 milestones triggered; MGD019 IND cleared B7-H3 franchise: enoblituzumab oral presentation at SITC; MGC018 Phase 1 study ini
Read more →MGNXMacroGenics Announces Date of Third Quarter 2018 Financial Results Conference Call
Rockville, MD, Oct. 31, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 7, 2018, the Company will release its financial results for the quarter ended September 30, 2018. The Company's management team will host a conference ca
Read more →MGNXMacroGenics and NanoString Enter Translational Research Collaboration to Identify and Develop Biomarkers in Immuno-Oncology
Translational Research Initiative Will Use PanCancer IO 360 Panel to Identify Predictive Signatures for MGD013 SEATTLE, Oct. 29, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagno
Read more →MGNXMacroGenics Announces Participation in Two Upcoming Investor Conferences
ROCKVILLE, MD, Sept. 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's
Read more →MGNXMacroGenics Announces Participation in Three Upcoming Investor Conferences
Rockville, MD, Aug. 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXMacroGenics to Present at Wedbush PacGrow Healthcare Conference
ROCKVILLE, MD, Aug. 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2nd Quarter 2018 Financial Results
ROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corp
Read more →MGNXMacroGenics Announces Date of Second Quarter 2018 Financial Results Conference Call
ROCKVILLE, MD, July 30, 2018 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, August 7, 2018, the Company will release its financial results for the quarter ended June 30, 2018. The Company's management team will host a conference call dis
Read more →MGNXMacroGenics to Present at Jefferies Global Healthcare Conference
ROCKVILLE, MD, June 05, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXMacroGenics to Present at Deutsche Bank Health Care Conference
ROCKVILLE, MD, May 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's ma
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results
ROCKVILLE, Md., May 07, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress up
Read more →MGNXMacroGenics Announces Date of First Quarter 2018 Financial Results Conference Call
ROCKVILLE, MD, April 30, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Monday, May 7, 2018, the Company will release its financial results for the quarter ended March 31, 2018. The Company's management team will host a conference call discussi
Read more →MGNXMacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ROCKVILLE, MD, April 02, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the closing of its
Read more →MGNXMacroGenics to Present at Cowen Health Care Conference
Rockville, MD, March 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2017 Financial Results
ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress u
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference Call
ROCKVILLE, MD, Feb. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on Tuesday, Feb
Read more →MGNXMacroGenics to Participate in Two Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 06, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's m
Read more →MGNXMacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
Rockville, MD, Jan. 23, 2018 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced completion of a pr
Read more →MGNXMacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Enters Research Collaboration with Roche to Develop a Novel Bispecific Molecule
ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorde
Read more →MGNXMacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte
ROCKVILLE, MD, Dec. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and i
Read more →MGNXMacroGenics Names Dr. Jay Siegel to its Board of Directors
ROCKVILLE, MD, Nov. 15, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and i
Read more →MGNXMacroGenics Announces Poster Presentations at 32nd Annual SITC Meeting 2017
ROCKVILLE, Maryland, Nov. 10, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results ROCKVILLE, MD
MacroGenics Provides Update on Corporate Progress and Third Quarter 2017 Financial Results ROCKVILLE, MD, November 8, 2017 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based th
Read more →MGNXMacroGenics to Present Phase 1 Data on Flotetuzumab, a CD123 x CD3 DART Molecule, at 59th Annual ASH Meeting
ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- – MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Announces Date of Third Quarter 2017 Financial Results Conference Call
ROCKVILLE, MD, Nov. 01, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 8, 2017, the Company will release its financial results for the quarter ended September 30, 2017. The Company's management team will host a conference
Read more →MGNXIncyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012
Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012 WILMINGTON, Del. AND ROCKVILLE, Md. - October 25, 2017 - Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies
Read more →MGNXMacroGenics Advances Two First-in-Class Clinical DART Molecules
First patient dosed with MGD013 (PD-1 x LAG-3 DART) IND submitted for MGD014 (HIV x CD3 DART) NIAID exercises option to advance MGD014 and develop second HIV-directed DART molecule ROCKVILLE, MD, Sept. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-
Read more →MGNXMacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen
ROCKVILLE, MD, Aug. 31, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics to Participate in Three Investor Conferences in September
ROCKVILLE, MD, Aug. 30, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics to Present at the Wedbush PacGrow Healthcare Conference
ROCKVILLE, MD, Aug. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results
ROCKVILLE, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and i
Read more →MGNXMacroGenics Announces Date of Second Quarter 2017 Financial Results Conference Call
ROCKVILLE, MD, July 26, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 2, 2017, the Company will release its financial results for the quarter ended June 30, 2017. The Company's management team will host a conference call disc
Read more →MGNXMacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017)
ROCKVILLE, MD, June 17, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 1 st Quarter 2017 Financial Results ROCKVILLE, MD
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results ROCKVILLE, MD, May 3, 2017 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeut
Read more →MGNXMacroGenics Announces Registered Direct Offering of Common Stock
Rockville, MD, April 27, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders
Read more →MGNXMacroGenics to Present at Two Upcoming Investor Conferences in May
Rockville, MD, April 26, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call
ROCKVILLE, MD, April 25, 2017 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 3, 2017, the Company will release its financial results for the quarter ended March 31, 2017. The Company's management team will host a conference call di
Read more →MGNXMacroGenics to Present at the Needham Healthcare Conference
Rockville, MD, March 29, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2016 Financial Results
ROCKVILLE, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and i
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call
ROCKVILLE, MD, Feb. 16, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and in
Read more →MGNXMacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
ROCKVILLE, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and i
Read more →MGNXMacroGenics Announces Appointments to Board of Directors
Rockville, MD, Jan. 25, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and i
Read more →MGNXMacroGenics to Present at the 35th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics’ MGD006 Granted Orphan Drug Status for AML by FDA
ROCKVILLE, MD, Jan. 05, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Highlights Progress at 2016 R&D Day
Advancement of HER2 franchise led by margetuximab Expansion and progression of B7-H3 franchise Introduction of PD-1 directed immuno-oncology franchise Clinical updates on multiple DART® studies underscore platform progress Pipeline poised to expand with at least 3 new INDs fr
Read more →MGNXMacroGenics Licenses Synthon’s Technology to Develop an Anti-B7-H3 ADC
ROCKVILLE, Md. and NIJMEGEN, the Netherlands, Dec. 12, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as we
Read more →MGNXMacroGenics to Host 2016 R&D Day
ROCKVILLE, MD, Dec. 08, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2016 Financial Results Continued expansion and advancement of product candidates Portfolio update planned for upcoming R&D Day on
MacroGenics Provides Update on Corporate Progress and Third Quarter 2016 Financial Results ROCKVILLE, MD, November 2, 2016 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based th
Read more →MGNXMacroGenics Announces Date of Third Quarter 2016 Financial Results Conference Call
Rockville, MD, Oct. 26, 2016 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 2, 2016, the Company will release its financial results for the quarter ended September 30, 2016. The Company's management team will host a conference
Read more →MGNXMacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Rockville, MD, Sept. 23, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Announces the Promotion of Three Executives
Rockville, MD, Sept. 20, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results MGD010 Phase 1 clinical DART data presented at EULAR Entered into collaboration with Janssen to develop MGD015 On track for thre
MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results ROCKVILLE, MD, August 3, 2016 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based the
Read more →MGNXMacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call
Rockville, MD, July 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 3, 2016, the Company will release its financial results for the quarter ended June 30, 2016. The Company's management team will host a conference call disc
Read more →MGNXMacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015
Rockville, MD, June 28, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer as well as autoimmune disorders and in
Read more →MGNXMacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016)
Bispecific molecule based on DART® platform simultaneously targets B-cell antigens, CD32B and CD79B MGD010 was well tolerated at all dose levels with no serious adverse effects ROCKVILLE, Maryland, June 10, 2016 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (NASDAQ: MGNX), a clinic
Read more →MGNXMacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer
MacroGenics licenses MGD015 to Janssen $75 Million upfront license fee paid to MacroGenics MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S. and Canada profit share MacroGenics may elect to co-promote in the United States Rockville
Read more →MGNXMacroGenics to Present MGD010 Clinical Data at EULAR 2016
ROCKVILLE, Maryland, May 11, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2016 Financial Results Eight molecules in clinical development, including six in immuno-oncology On track for three new IND submissions in 2016-2017 Pro
MacroGenics Provides Update on Corporate Progress and First Quarter 2016 Financial Results ROCKVILLE, MD, May 4, 2016 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therape
Read more →MGNXMacroGenics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Rockville, MD, May 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and in
Read more →MGNXMacroGenics Announces Date of First Quarter 2016 Financial Results Conference Call
ROCKVILLE, Md., April 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 4, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call discu
Read more →MGNXMacroGenics Presents Data from Five Preclinical Programs at AACR Annual Meeting 2016
ROCKVILLE, Maryland, April 19, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorder
Read more →MGNXMacroGenics to Present at the 15th Annual Needham Healthcare Conference
Rockville, MD, April 06, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Announces Five Posters at AACR Annual Meeting 2016
ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorde
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2015 Financial Results Eight molecules in clinical development, including six in immuno-oncology Multi-national Phase 1b/2 gastric cancer study initiated evaluating t
MacroGenics Provides Update on Corporate Progress and 2015 Financial Results ROCKVILLE, MD, February 29, 2016 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics fo
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2015 Financial Results Conference Call
ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Rockville, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference
ROCKVILLE, Md., Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results Bi-specific antibody leadership - fifth DART molecule (MGD009) enters clinical testing B7-H3 franchise advances - Encouraging ini
MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results Bi-specific antibody leadership - fifth DART molecule (MGD009) enters clinical testing B7-H3 franchise advances - Encouraging initial clinical results from ongoing enoblituzumab (MGA271)
Read more →MGNXMacroGenics Regains European and Other Regional Rights to Enoblituzumab - Servier does not exercise option to license rights for enoblituzumab in its specified territories - MacroGenics advances enoblituzumab and pursues
MacroGenics Regains European and Other Regional Rights to Enoblituzumab ROCKVILLE, MD -- Oct. 28, 2015 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the t
Read more →MGNXMacroGenics Announces Date of Third Quarter 2015 Financial Results Conference Call
Rockville, MD, Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015, the Company will release its financial results for the quarter ended September 30, 2015. The Company's management team will host a conference cal
Read more →MGNXMacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer
ROCKVILLE, MD and KENILWORTH, NJ , Oct. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disor
Read more →MGNXMacroGenics Highlights Progress at 2015 R&D Day
Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trial B7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1 Proprietary immune checkpoint PD-1 x LAG-3 DART molecule (MGD013) introduced HIV DART and Trident™ tri-specific platform introduce
Read more →MGNXMacroGenics to Host 2015 R&D Day
ROCKVILLE, Md., Oct. 06, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Announces Presentation at 30th Annual SITC Meeting 2015
ROCKVILLE, Maryland, Oct. 01, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorder
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2015 Financial Results
-- Fourth bi-specific DART® molecule, MGD011, in clinical testing -- Margetuximab Phase 3 SOPHIA metastatic breast cancer study initiated -- Balance sheet strengthened with completion of $141 million equity offering ROCKVILLE, Md., Aug. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics
Read more →MGNXMacroGenics to Present at the 2015 Wedbush PacGrow Healthcare Conference
Rockville, MD, Aug. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and i
Read more →MGNXMacroGenics Announces Date of Second Quarter 2015 Financial Results Conference Call
ROCKVILLE, Md, July 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 5, 2015, the Company will release its financial results for the quarter ended June 30, 2015. The Company's management team will host a conference call discu
Read more →MGNXMacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015
ROCKVILLE, Md., May 30, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and in
Read more →MGNXMacroGenics Preclinical Research on MGD006 DART(R) Molecule Published in Science Translational Medicine
- MGD006 Enables T Cells to Recognize and Kill Leukemia Cells - Research Paved the Way for Human Clinical Trials ROCKVILLE, Md., May 27, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing i
Read more →MGNXMacroGenics Announces Presentation at ASCO Annual Meeting 2015
ROCKVILLE, Md., May 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and in
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results
-- Company's third bi-specific DART molecule, MGD010, in clinical testing -- FDA clears IND for fourth DART, MGD011 - Janssen to initiate clinical testing -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 ROCKVILLE, Md., May 6, 2015 (GLOBE NE
Read more →MGNXMacroGenics Announces Date of First Quarter 2015 Financial Results Conference Call
ROCKVILLE, Md., April 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Wednesday, May 6, 2015, the Company will release its financial results for the quarter ended March 31, 2015. The Company's management team will host a conference call discus
Read more →MGNXMacroGenics Announces Participation in Two Investor Conferences in May
ROCKVILLE, Md., April 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Presents Pre-Clinical Data on its Multivalent DR5 DART at the AACR Annual Meeting
ROCKVILLE, Md., April 20, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics Announces Presentations at AACR Annual Meeting 2015
ROCKVILLE, Md., April 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and
Read more →MGNXMacroGenics to Present at the 14th Annual Needham Healthcare Conference
Rockville, MD, April 7, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders an
Read more →MGNXMacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders
ROCKVILLE, Md., March 16, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2014 Financial Results
-- Four oncology molecules in clinical development, including two bi-specific DART molecules -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 -- Cash runway extends into 2018 ROCKVILLE, Md., March 3, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc
Read more →MGNXMacroGenics to Present at the Roth Capital Partners 27th Annual Growth Stock Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scot
Read more →MGNXMacroGenics Announces Date of Fourth Quarter and Full Year 2014 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, March 3, 2015, the Company will release its financial results for the fourth quarter and full year 2014. The Company's management team will host a conference call discussing the Company's financial results and
Read more →MGNXMacroGenics to Present at the Leerink Global Healthcare Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scot
Read more →MGNXMacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies ROCKVILLE, Md., January 27 , 2015 - MacroGenics, Inc. (NASDAQ: MGNX ), a clinical-stage
MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies ROCKVILLE, Md., January 27, 2015 - MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and develop
Read more →MGNXMacroGenics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, today announced t
Read more →MGNXMacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies MacroGenics licenses MGD011 (CD19 x CD3 DART ) to Janssen $50 million upfront license fee paid to Mac
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies ROCKVILLE, Maryland - December 22, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing inn
Read more →MGNXMacroGenics Announces Presentation of Pre-clinical Data on new DART(r) Candidate MGD011 at 56th Annual Meeting of the American Society of Hematology
Rockville, MD, Dec. 6, 2014 (GLOBE NEWSWIRE) -- December 6, 2014 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as auto
Read more →MGNXMacroGenics to Present at the Oppenheimer 25th Annual Healthcare Conference
ROCKVILLE, Md., Dec. 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders an
Read more →MGNXMacroGenics to Present at the Stifel 2014 Healthcare Conference
ROCKVILLE, Md., Nov. 12, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Md., November 12, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of canc
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Third Quarter 2014 Financial Results
-- Four oncology molecules in clinical development; on track to have six by 2015 year-end -- Margetuximab Phase 3 study in metastatic breast cancer to initiate in 2015 -- MGD007 (gpA33 x CD3 DART) first patients dosed in colorectal cancer -- MGD011 (CD19 x CD3 DART) introduced
Read more →MGNXMacroGenics Announces Pre-clinical Data to be Presented at ASH 2014 Annual Meeting
ROCKVILLE, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Md., November 6, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,
Read more →MGNXMacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium
Rockville, MD, Oct. 30, 2014 (GLOBE NEWSWIRE) -- MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium ROCKVILLE, Md., October 30, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and deve
Read more →MGNXMacroGenics Announces Date of Third Quarter 2014 Financial Results Conference Call
ROCKVILLE, Md., October 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, November 11, 2014, the Company will release its financial results for the quarter ended September 30, 2014. The Company's management team will host a confere
Read more →MGNXMacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics
ROCKVILLE, Maryland and OSAKA, Japan, Sept. 29, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Maryland and OSAKA, Japan - September 29, 2014 - MacroGenics, Inc. (NASDAQ: MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration a
Read more →MGNXMacroGenics to Present at the Wedbush 2014 Life Sciences Management Access Conference
ROCKVILLE, Md., Aug. 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announce
Read more →MGNXMacroGenics Provides Update on Corporate Progress and Second Quarter 2014 Financial Results
ROCKVILLE, Md., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today provided
Read more →MGNXMacroGenics Announces Date of Second Quarter 2014 Financial Results Conference Call
ROCKVILLE, Md., July 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, August 5, 2014, the Company will release its financial results for the quarter ended June 30, 2014. The Company's management team will host a conference call discuss
Read more →MGNXMacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients
ROCKVILLE, Md., July 24, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announ
Read more →MGNXMacroGenics Initiates Phase 1 Study of MGD006 for the Treatment of Acute Myeloid Leukemia
ROCKVILLE, Md., June 19, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune disease, today announc
Read more →MGNXMacroGenics and Takeda Enter Strategic Alliance to Develop DART for Treatment of Autoimmune Disorders Option-based collaboration around MGD010 product candidate Incorporates MacroGenics proprietary DART technology for bi
MacroGenics and Takeda Enter Strategic Alliance to Develop DART for Treatment of Autoimmune Disorders ROCKVILLE, Maryland, May 27, 2014 and OSAKA, Japan, May 28, 2014 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and develo
Read more →MGNXMacroGenics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
ROCKVILLE, Md., May 7, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced
Read more →MGNXMacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results
Clinical study of first DART, MGD006, to commence in Second Quarter 2014 Phase 3 margetuximab gastroesophageal "MAGENTA" study poised for initiation in second half 2014 ROCKVILLE, Md., May 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmace
Read more →MGNXMacroGenics Presents Pre-Clinical Data on Inhibition of Autoimmune Diseases With DART Candidate MGD010 at IMMUNOLOGY 2014
ROCKVILLE, Md., May 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announce
Read more →MGNXMacroGenics Appoints Atul Saran as Senior Vice President and General Counsel
ROCKVILLE, Md., April 30, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announ
Read more →MGNXMacroGenics Announces Date of First Quarter 2014 Financial Results Conference Call
ROCKVILLE, Md., April 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, May 6, 2014, the Company will release its financial results for the quarter ended March 31, 2014. The Company's management team will host a conference call discussi
Read more →MGNXMacroGenics to Present Pre-Clinical Data on Novel DART Candidate MGD010 for Autoimmune Disorders at IMMUNOLOGY 2014
ROCKVILLE, Md., April 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today annou
Read more →MGNXMacroGenics Presents Pre-Clinical Data Demonstrating Potent Activity With Colorectal Cancer Product Candidate MGD007 at the AACR Annual Meeting
ROCKVILLE, Md., April 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announ
Read more →MGNXMacroGenics to Present at the 13th Annual Needham Healthcare Conference
ROCKVILLE, Md., April 1, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announc
Read more →MGNXMacroGenics to Present Pre-clinical Data on MGD007 at the AACR Annual Meeting
ROCKVILLE, Md., March 31, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today annou
Read more →MGNXMacroGenics Provides Update on Corporate Progress and 2013 Financial Results Six immuno-oncology clinical programs projected by end of 2015 Cash runway extends into 2017 ROCKVILLE, Md.
MacroGenics Provides Update on Corporate Progress and 2013 Financial Results Six immuno-oncology clinical programs projected by end of 2015 Cash runway extends into 2017 ROCKVILLE, Md., March 20, 2014 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company
Read more →MGNXMacroGenics Announces Date of Year End 2013 Financial Results Conference Call
ROCKVILLE, Md., March 13, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Thursday, March 20, 2014, the Company will release its financial results for the year ended December 31, 2013. The Company's management team will host a conference call disc
Read more →MGNXMacroGenics Appoints Matthew Fust to Its Board of Directors
ROCKVILLE, Md., March 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chai
Read more →MGNXMacroGenics to Present at the 26th Annual ROTH Conference
ROCKVILLE, Md., March 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announc
Read more →MGNXMacroGenics Achieves Milestone as Servier Exercises Option to Develop and Commercialize DART-Based Candidate, MGD006
Successful Advancement of Lead DART Molecule and Option Exercise Triggers $20 Million in Payments MacroGenics Retains Full Rights to MGD006 in Multiple Major Markets ROCKVILLE, Md. and SURESNES, France, Feb. 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinic
Read more →MGNXMacroGenics Announces Publication of Cancer Stem Cell Research in Lung Cancer
ROCKVILLE, Md., Dec. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announc
Read more →MGNXMacroGenics Announces Presentation of Pre-Clinical Data on DART(R) Molecule Targeting CD123-Positive Leukemic Stem Cells at 55th Annual Meeting of the American Society of Hematology
ROCKVILLE, Md., Dec. 9, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announce
Read more →MGNXMacroGenics Provides Corporate Progress Update and Third Quarter 2013 Financial Results ROCKVILLE, Md.
MacroGenics Provides Corporate Progress Update and Third Quarter 2013 Financial Results ROCKVILLE, Md., November 12, 2013 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based ther
Read more →MGNXMacroGenics to Present Pre-Clinical Data on Targeting CD123-Positive Leukemic Stem Cells at the 55th ASH Annual Meeting
ROCKVILLE, Md., Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announc
Read more →MGNXMacroGenics DART Therapeutic Selected by Boehringer Ingelheim as a Bi-Specific Pre-Clinical Development Candidate
ROCKVILLE, Md., Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that Boehringer Ingelheim has nominated a bi-specific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting (DART ) technology for pre-clinical developm
Read more →MGNXMacroGenics Announces Timing for Third Quarter 2013 Financial Results and Conference Call
ROCKVILLE, Md., Nov. 5, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, November 12, 2013, the Company will release its financial results for the third quarter ended September 30, 2013. The Company's management team will host a conference
Read more →MGNXMacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option ROCKVILLE, Md.
MacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option ROCKVILLE, Md., October 16, 2013 MacroGenics, Inc. (NASDAQ: MGNX) today announced the closing of its initial public offering of 5,750,000 shares of its common stock, including 7
Read more →MGNXMacroGenics, Inc. [MGNX] to Ring The NASDAQ Stock Market Closing Bell in Celebration of IPO
ADVISORY, Oct. 10, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. [MGNX], a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, will visit the NASDAQ Mar
Read more →Competitive Position
How MGNX ranks across every disease it competes inCompetitive Position is a premium feature
See how MGNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial